RecruitingNCT07325864
Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site
Sponsor
European Institute of Oncology
Enrollment
25 participants
Start Date
Dec 18, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
investigate the molecular differences between primitive lung cancer and the metastatic site.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study aims to better understand the genetic make-up of lung cancers and how the primary tumor compares to cancer that has spread to other parts of the body. By analyzing tumor DNA with advanced gene sequencing, researchers hope to improve how lung cancer is treated in a more personalized way.
**You may be eligible if...**
- You are 18 years or older and healthy enough to tolerate surgery
- Your surgical risk has been assessed as low based on heart and lung function
- You are willing to follow the study procedures
- Tumor tissue can be collected and used for DNA analysis and genetic testing
**You may NOT be eligible if...**
- You are a woman who is pregnant, breastfeeding, or planning to become pregnant during the study
- You have another illness or physical condition that makes participation unsafe
- You have a recent or ongoing severe infection
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07325864
Related Trials
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT052833304 locations
Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib
NCT0662083527 locations
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143207 locations
Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE
NCT075591231 location
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
NCT041141361 location